ERG, MN1, and BAALC expression. (A) EFS for patients with high versus low ERG expression. (B) EFS in FLT3-ITD–negative patients: high versus low ERG expression. (C) EFS for patients with high versus low MN1 expression. (D) EFS for non-inv(16)/t(16,16) patients: high versus low MN1 expression. (E) EFS for patients with high versus low BAALC expression.